Phase 2 RCT in 65 children with relapsed/refractory high-risk neuroblastoma: adding dinutuximab beta to temozolomide-based chemotherapy gave response rates of 30.2% vs 18.2%; neurotoxicity was more common (grade 1-2: 26% vs 9%).
RCTn = 65
Gray et al. Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial